HomeProfessionals Resident Doctor, MSc, Doctor Nguyen Thi Thu Ha
Resident Doctor, MSc, Doctor
Nguyen Thi Thu Ha
Booking
Overview

Dr. Ha has many years of experience studying and working in the field of medical oncology. She graduated from Hanoi Medical University in 2018 and continued her training through the residency program in oncology, earning a Master’s degree in Oncology from Hanoi Medical University. In addition, Dr. Ha continuously strives to advance her professional knowledge by participating in scientific conferences and seminars focused on medical oncology treatment.

Her areas of expertise include chemotherapy, targeted therapy, and immunotherapy for various cancers, especially lung cancer, gastrointestinal cancers, and breast cancer. She is also experienced in managing complications related to chemotherapy and immunotherapy, as well as providing palliative care for cancer patients, including pain management, nutritional support, common infections in oncology, and other severe cancer-related complications.

Positions
Medical Oncologist
Specialties
Oncology - Radiotherapy
Years of experience
years
Services
  • Breast Cancer - Gynecology
  • Gastrointestinal Cancer
  • Head and Neck Cancer
  • Lung Cancer

09/2018 – 10/2021: Resident Doctor in Oncology – Hanoi Medical University


09/2012 – 08/2018: General Medicine Student – Hanoi Medical University


11/2021 – Present: Medical Oncologist – Center for Oncology and Radiotherapy, Vinmec Times City International Hospital.


03/2019 – 10/2021: Resident Doctor in Oncology – K Hospital.


  • Initial Evaluation of Pembrolizumab Monotherapy in Advanced Non-Small Cell Lung Cancer at K Hospital, Vietnam Medical Journal, August – Issue 2, 2020.
  • Progress-Free Survival and Associated Factors in Non-Small Cell Lung Cancer Patients Treated with Pembrolizumab, Vietnam Medical Journal, January – Issue 1, 2023.
  • Evaluation of Treatment Outcomes for Medullary Thyroid Cancer at K Hospital, 2016-2021, Vietnamese Journal of Oncology, Issue 02-2022.
  • Safety Evaluation of Pembrolizumab Immune Checkpoint Inhibitor in Advanced Non-Small Cell Lung Cancer at K Hospital, Clinical Medicine Journal – Hue Central Hospital, Issue 67, 2021.